Dosing & Timing

Human study doses

There are no completed human oncology trials defining an apigenin dose for cancer treatment or adjunctive use.

Available human dosing information comes from:

• pharmacokinetic studies using oral doses around 60–100 mg

• dietary exposure studies, including roughly 35 g fresh parsley per day, which delivered about 18 mg apigenin and produced peak plasma concentrations near 337 nmol/L

• commercial supplements, which commonly provide 50–100 mg per day, with some products listing substantially higher daily amounts

These exposure data help frame feasibility. They do not establish a therapeutic oncology dose.

Preclinical dose context

Most anticancer animal studies used doses ranging from low parenteral dosing to roughly 150–300 mg/kg by oral gavage.

When scaled to human-equivalent doses, many exceed what is reliably achievable with standard oral supplementation. That gap is one reason formulation work became so important in the apigenin literature.

These animal doses should not be used as direct human supplementation guidance. Species differences, route differences, and formulation differences make simple conversion invalid.

Formulation-adjusted dosing logic

Liposomal and phospholipid-complex formulations aim to improve oral bioavailability by protecting the compound during gastrointestinal transit and improving uptake.

Early formulation data suggest better pharmacokinetic performance. Whether this translates into oncology-relevant tissue exposure in humans remains unproven.

Timing with food

Because apigenin is lipophilic, a liposomal formulation is a rational choice when bioavailability is the priority.

If standard powder is used, taking it with a meal that contains some fat may support absorption. Consistent timing may also help reduce highly variable sporadic exposure.

What is clearly established

• There is no oncology-standard apigenin dose.

• Human pharmacokinetic doses are not the same as proven therapeutic doses.

• Preclinical doses should not be used as a direct human dosing guide.

• Liposomal formulations may improve exposure, but lack oncology-specific clinical validation.

References

• Chmielewska M, et al. Does Oral Apigenin Have Real Potential for a Therapeutic Effect in Cancer?

• Hou M, et al. Recent advancement in bioeffect, metabolism, stability, and delivery systems of apigenin

• Tang D, et al. Enhancement of in vitro transcellular absorption and in vivo oral bioavailability of apigenin using self-nanoemulsifying drug delivery system